Horizon Technology Finance closed a $10 million venture loan facility to Aerobiotix, LLC, of which Horizon funded $5 million, and a private investment vehicle managed by Horizon Technology Finance Management LLC, Horizon's adviser, funded $5 million.

Aerobiotix manufactures air disinfection systems for medical, healthcare and community facilities that eliminate airborne pathogens to optimize indoor air quality. Utilizing a proprietary ultraviolet photolytic chamber, Aerobiotix's Illuvia® air disinfection system breaks the DNA codes of pathogens and prevent healthcare-acquired infections that can cause major complications in patients.  Prominent investors in Aerobiotix include Vivo Capital and Asahi Kasei Corporate Venture Capital, and Aerobiotix will use the loan proceeds for general growth and working capital purposes.

"Aerobiotix has developed a needed solution to prevent healthcare-acquired infections, leading to optimal outcomes for both patients and hospitals," said Gerald A. Michaud, President of Horizon. "Along with focusing on healthcare-oriented facilities, Aerobiotix's proprietary offerings can also be purposed for many other markets, including schools, high-density residential and commercial office buildings. We are pleased to support Aerobiotix's mission and to assist in Aerobiotix's continued growth."

"We are thrilled with Horizon's support as we continue to meet a surging demand in healthcare and hospitals for transformational air quality technology," said David Kirschman, MD, Aerobiotix founder and Chief Executive Officer. "Aerobiotix's innovative devices are already being used in over 170 healthcare locations, improving patient and staff safety on a daily basis and helping to reduce unnecessary expenses for both patients and hospitals. We look forward to utilizing Horizon's support to further expand our market share and develop additional indoor air quality solutions."